Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > PharmaEngine Receives Approval of US IND Application for a Phase II Study of PEP02 (Liposome Irinotecan Injection) in Pancreatic Cancer

Abstract:
PharmaEngine, Inc. announced today that it has received approval of an Investigational New Drug (IND) application from the U.S. FDA for PEP02, a liposome formulation of irinotecan in a phase II study in patients with metastatic pancreatic cancer. Previous phase I data showed excellent pharmacokinetics, tolerability and efficacy of PEP02 in advanced solid tumor patients in a poster presented at 2008 ASCO Annual Meeting.

PharmaEngine Receives Approval of US IND Application for a Phase II Study of PEP02 (Liposome Irinotecan Injection) in Pancreatic Cancer

Taipei, Taiwan | Posted on December 3rd, 2008

During the pre-IND meeting this September, the FDA concurred with PharmaEngine's pancreatic cancer study design, as well as the overall development strategy for pancreatic, gastric, and colorectal cancers. Subsequently, the company completed IND submission in October, and received the safe-to-proceed letter in November. "I am very delighted that we have achieved an important milestone of IND approval for our second phase II study," said Grace Yeh, Ph.D., President and Chief Executive Officer. "PharmaEngine is most likely the first Taiwan company which has obtained regulatory approvals for phase II studies in Asia, Europe and the US, based on the phase I data generated in Taiwan."

The phase II study is an open-label, multi-national, optimal 2-stage design to be conducted in the US and Taiwan. PharmaEngine plans to enroll metastatic pancreatic cancer patients who failed gemcitabine containing regimen during 2009. There is no standard second line treatment for this nearly fatal cancer.

About PEP02

PEP02 is irinotecan hydrochloride encapsulated in a liposome formulation. Hermes Biosciences, Inc. (South San Francisco, CA, USA) invented the nanoparticle formulation, and licensed it to PharmaEngine to develop, manufacture, and commercialize in Asia and Europe. Irinotecan (CPT-11) is a topoisomerase I inhibitor which has shown significant activity in a variety of tumor types. The Irinotecan Injection (Campto® or Camptosar®) has been approved for the treatment of colorectal cancer with sales of nearly US$1 billion in 2007. However, at high dosage, irinotecan causes severe diarrhea and myelosuppression, which is recognized as the dose-limiting toxicity and limits the use of more aggressive irinotecan therapy.

In the phase I clinical studies in advanced solid tumor patients, PEP02 given as a single agent or in combination with other chemotherapeutic agents showed a better pharmacokinetic, safety and efficacy profile, which compared favorably to the published data of unencapsulated irinotecan, or other types of formulations.

In early 2008, PharmaEngine initiated a multi-national (Europe and Asia), randomized phase II study of PEP02 as a second line treatment in gastric cancer patients. The study is estimated to complete patient enrollment in the first half of 2009.

####

About PharmaEngine, Inc.
PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003, and funded by TTY Biopharm and Taiwan venture capitals for NTD630 million (around US$20 million) in 2004. The company focuses on the development of new drugs to treat cancer and Asian prevalent diseases.

For more information, please click here

Contacts:
Peter Wu
+886(2)-2515-8228
Senior Manager of Business Development
Fax: +886(2)-2515-7558

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Strength in numbers: Researchers develop the first-ever quantum device that detects and corrects its own errors March 4th, 2015

New research could lead to more efficient electrical energy storage March 4th, 2015

Energy-generating cloth could replace batteries in wearable devices March 4th, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015

Govt.-Legislation/Regulation/Funding/Policy

New research could lead to more efficient electrical energy storage March 4th, 2015

Energy-generating cloth could replace batteries in wearable devices March 4th, 2015

The taming of magnetic vortices: Unified theory for skyrmion-materials March 3rd, 2015

Black phosphorus is new 'wonder material' for improving optical communication March 3rd, 2015

Nanomedicine

Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes March 4th, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015

Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015

Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015

Announcements

Experiment and theory unite at last in debate over microbial nanowires: New model and experiments settle debate over metallic-like conductivity of microbial nanowires in bacterium March 4th, 2015

Magnetic vortices in nanodisks reveal information: Researchers from Dresden and Jülich use microwaves to read out information from smallest storage devices March 4th, 2015

CiQUS researchers obtain high-quality perovskites over large areas by a chemical method March 4th, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE